Hims & Hers Health Inc (NYSE:HIMS) is one of the best performing stocks on the New York Stock Exchange (NYSE) today, up 4.5% to trade at $25.52. The telehealth name is buzzing after the Food and Drug ...

Lawsuits don’t often end in partnerships. And yet that is the strange but true tale involving Hims & Hers and drug manufacturer Novo Nordisk. Last month, Novo Nordisk sued Hims & Hers over its sale ...

Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health platform, ending a legal dispute that erupted last month. The ...

This is read by an automated voice. Please report any issues or inconsistencies here. Telehealth company Hims & Hers dropped its plan to offer a knockoff version of ...

Hims & Hers and Novo Nordisk have had a tumultuous relationship over the past couple of years. The companies formed a short-lived commercial partnership last year, only for Novo Nordisk to walk away, ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk's branded weight loss ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

CHONGQING, CHINA - JULY 30: In this photo illustration, a smartphone displays the logo of Hims & Hers Health Inc. (NYSE: HIMS), a telehealth company offering personal wellness and healthcare products ...

March 9 (Reuters) - Hims & Hers' (HIMS.N), opens new tab shares were up over 40% on Monday, after Novo Nordisk (NOVOb.CO), opens new tab agreed to sell its blockbuster Wegovy and ‌Ozempic drugs ...

Hims & Hers Health Inc. surged after Novo Nordisk A/S was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform. Novo and Hims plan ...